Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





FENTHION								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 55-38-9; **Chemical Formula:** C10H15O3PS2
Previously, OSHA had no limit for fenthion. The ACGIH has a TLV-TWA of 0.2 mg/m3, with a skin notation. The proposed PEL was 0.2 mg/m3, with a skin notation, and the final rule establishes this limit and a skin notation. Fenthion is an oily, yellow- to tan-colored liquid that smells slightly like garlic.
The primary health effect associated with exposure to fenthion is plasma cholinesterase inhibition. The oral LD(50) values for the rat and rabbit are 215 and 150 mg/kg, respectively, and the dermal LD(50) in rats is 330 mg/kg (Farm Chemicals Handbook 1976/Ex. 1-1147b; NIOSH 1977j, as cited in ACGIH 1986/Ex. 1-3, p. 268). Rats given single intramuscular injections of 5, 25, or 50 mg/kg of fenthion exhibited both enduring electroretinogram changes (ERG) and changes in cholinesterase activity; pseudocholinesterase activity in the plasma dropped to 50 percent of normal on the fourth day after injection. The retinal effects of fenthion persisted for as long as 50 days (Imai 1975/Ex. 1-910). Groups of Donryn rats fed 300 ppm fenthion daily showed symptoms of organophosphate intoxication, including nervousness, general spasms, diarrhea, salivation, and ophthalmologic effects (Kawai, Tojo, Miyazawa et al. 1976/Ex. 1-1157). The no-effect inhalation level for rats has been reported to be 1 mg/m3 for exposures to the aerosol of six hours/day, five days/week for three weeks; at a concentration of 3 mg/m3, cholinesterase inhibition was found (Thyssen 1979, as cited in ACGIH 1986/Ex. 1-3, p. 267). The four-hour inhalation LC(50) in the rat is between 800 and 1200 mg/m3 (Thyssen 1978, as cited in ACGIH 1986/Ex. 1-3, p. 267).
No mutagenic, carcinogenic, or reproductive effects have been reported (Shirasu, Moriya, Kato et al. 1976/Ex. 1-1097; Hanna and Dyer 1975/Ex. 1-485; and WHO 1976, Food and Agriculture Organization (FAO/WHO) 1979, Oesch 1977, Simmon, Mitchell, and Jergenson 1977, and Herbold 1980, all as cited in ACGIH 1986/Ex. 1-3, p. 268). Single and repeated applications of the compound produced no delayed neurotoxic effects in chickens (WHO 1972, as cited in ACGIH 1986/Ex. 1-3, p. 268). Two-year feeding studies of rhesus monkeys showed plasma cholinesterase inhibition at the highest oral dose given, i.e., 0.2 mg/kg daily (Rosenblum 1980, as cited in ACGIH 1986/Ex. 1-3, p. 268).
Griffin, Rosenblum, and Coulston (1979, as cited in ACGIH 1986/Ex. 1-3, p. 268) reported cholinesterase depression in humans at oral doses of 0.07 mg/kg daily for four weeks, but no effect was observed at 0.02 mg/kg. The lowest lethal dose for humans is 50 mg/kg (Farm Chemicals Handbook 1976/Ex. 1-1147b; NIOSH 1977j, as cited in ACGIH 1986/Ex. 1-3, p. 100).
NIOSH (Ex. 8-47, Table N2) does not concur with OSHA’s limit for fenthion because a significantly increased incidence of tumors was seen in male mice exposed to fenthion (NCI 1979e, as cited in ACGIH 1986/Ex. 1-3, p. 268) and fenthion is also a mutagen, embryotoxin, and teratogen (Chen, Sirianni, and Huang 1985 and Budreau and Singh 1973, both as cited in NIOSH/Ex. 150, Comments on Fenthion). OSHA will monitor the toxicological literature on fenthion; however, the Agency believes that the new PEL will protect exposed workers from any of the adverse effects associated with exposure to this substance. No other comments on fenthion were received.
In the final rule, OSHA is establishing an 8-hour TWA limit of 0.2 mg/m3, with a skin notation, for fenthion. The Agency concludes that these limits will protect workers against the significant risk of cholinergic effects associated with exposures to this substance at the levels formerly permitted by the absence of any OSHA limit. A skin notation is established because of evidence that fenthion is toxic when absorbed through the skin. OSHA finds that cholinesterase inhibition constitutes a material impairment of health.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue